European Economic
and Social Committee
Pharmaceutical strategy
The EESC:
- welcomes the fact that the new pharmaceutical strategy demonstrates the intention to promote the competitiveness of the related industry in Europe but also to ensure the provision of safe, high-quality and bearable medicines and to ensure the financial sustainability of Member States' health systems;
- stresses the challenge that common strategies represent for drug research and development, as well as for pricing;
- considers it urgent to review the legal framework currently applicable to medicines, to adapt it and to attach stricter conditions regarding their affordability and availability;
- stresses the essential role of an operating, fair and effective single market, which also encourages, and also rewards, real medical advances that have real added value for health care, while also working to strengthen competition, with a view to ensuring equitable and financially sustainable access to medicines.
For more information please contact the INT Section Secretariat.
Downloads
Recommended for you
Pharmaceutical package
Opinion
Key pointsThe EESC:supports the aim to improve the availability and accessibility of affordable medicines and boost the competitiveness as well as attractiveness of the EU pharmaceutical industry…
Pharmaceutical package
News
Background The pharmaceutical industry is one of the largest and most economically important industries in the European Union, employing around 840 000 people directly and generating three…
Developing a European Centre of Clinical Excellence for Pharmaceuticals
Opinion
Key pointsThe EESC:recommends establishing a European centre of clinical excellence (ECCE) as a non-binding EU reference body to translate scientific evidence into high-quality clinical guidance,…
A European Innovation Stress Test for an innovative and forward-looking industrial policy: the example of the pharmaceutical sector
Opinion
Pharmaceutical package: the EU needs to be more strategic
News
The long-awaited updating of EU pharma legislation offers potential benefits for Europeans but should give more consideration to strategic autonomy The proposed revamp of EU regulation relating to…